I don’t envy IRBs. In the absence of clear guidance on social media and patient recruitment, they are in a difficult spot. Despite the difficulty, the solution is not to hope social media goes away. It won’t. Internet users have developed a taste for dynamic interactive content, and they have no desire to revisit the […]
Electronic Informed Consent: Types and Technologies
Wondering if electronic informed consent is right for your clinical research study? My 2-part series will help you answer that question. Mitchell Parrish of Quorum IRB recently led a webinar about electronic informed consent, which included discussion of regulatory and other considerations. In this series, I summarize the information presented by Parrish, as well as […]
Electronic Informed Consent: Possibilities, Benefits, and Challenges
The clinical research community is showing greater interest in electronic informed consent. And they should. Electronic consenting offers benefits that traditional paper-based consenting does not. But with electronic consenting technology comes new complexity. To address the regulatory and IRB complexity of electronic consenting, Quorum Review IRB recently hosted a webinar presented by Mitchell Parrish. In […]
Patient Recruitment: Regulatory & IRB Considerations of Social Media
Many questions remain regarding social media’s use for patient recruitment, particularly with regard to regulatory and IRB considerations. Though pharma marketers are breathlessly awaiting the twice-delayed FDA guidance on social media, this guidance will be of little use to the clinical research industry, which has unique regulatory constraints. This informational void is further exacerbated by […]
